The RESILIENCE trial will use Cardiac Magnetic Resonance (CMR) as the main outcome measure methodology, and patients enrolled in the trial will undergo 3 scans across the duration of the study. Anthracycline-induced cardiotoxicity (AIC) will be diagnosed based on changes in left ventricular systolic function as evaluated by CMR.
Despite CMR is universally recognized as the gold standard technique for the evaluation of the heart, it is not universally used. One of the main reasons for this is that image acquisition takes a long time (45 to 60 min for a comprehensive protocol). This long duration results in low availability of the equipment in the hospitals, and also in patient´s discomfort. Members of the RESILIENCE consortium have developed a revolutionary CMR technique allowing a massive reduction in the time of scan. This new 3D single breath-hold CMR methodology is named Enhance SENSE by Static Outer volume Subtraction (ESSOS) This novel methodology might revolutionize the field of CMR and increase patient access to this technique. In addition, this technique will reduce patient discomfort, something very relevant for vulnerable populations, such as the elderly, the pediatric. The RESILIENCE project will validate this new methodology (as compared to the currently used).